{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:11:27Z","timestamp":1790957487917,"version":"4.1.0"},"reference-count":17,"publisher":"S. Karger AG","issue":"9-10","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Nephrol"],"published-print":{"date-parts":[[2023]]},"abstract":"<b><i>Introduction:<\/i><\/b> In FIDELIO-DKD, finerenone significantly improved cardiorenal outcomes in patients with chronic kidney disease and type 2 diabetes (T2D). This post hoc analysis explores finerenone in patients from the Asian region. <b><i>Methods:<\/i><\/b> In FIDELIO-DKD, 5,674 patients with T2D and urine albumin-to-creatinine ratio (UACR) \u226530\u2013&lt;300 mg\/g and estimated glomerular filtration rate (eGFR) \u226525\u2013&lt;60 mL\/min\/1.73 m<sup>2<\/sup> or UACR \u2265300\u2013\u22645,000 mg\/g and eGFR \u226525\u2013&lt;75 mL\/min\/1.73 m<sup>2<\/sup>, treated with optimized renin-angiotensin system blockade, were randomized 1:1 to finerenone or placebo. Efficacy outcomes included a primary kidney composite (time to kidney failure, sustained decrease of \u226540% in eGFR from baseline, and death from renal causes) and secondary cardiovascular (CV) (time to CV death, non-fatal myocardial infarction, non-fatal stroke, or hospitalization for heart failure) and kidney (time to kidney failure, sustained decrease of \u226557% in eGFR from baseline, and death from renal causes) composites. <b><i>Results:<\/i><\/b> Of 1,327 patients in the Asian subgroup, 665 received finerenone. Finerenone reduced the \u226540% and \u226557% eGFR kidney and CV composite outcomes versus placebo in the Asian subgroup (hazard ratio [HR]: 0.70; 95% confidence interval [CI]: 0.56\u20130.87, HR: 0.73; 95% CI: 0.55\u20130.97, and HR: 0.85; 95% CI: 0.59\u20131.21, respectively), with no apparent differences versus patients from the rest of the world (HR: 0.88; 95% CI: 0.77\u20131.02; <i>p<\/i> interaction 0.09, HR: 0.78; 95% CI: 0.64\u20130.95; <i>p<\/i> interaction 0.71, and HR: 0.86; 95% CI: 0.74\u20131.00; <i>p<\/i> interaction 0.95, respectively). The safety profile of finerenone was similar across subgroups. <b><i>Conclusion:<\/i><\/b> Finerenone produces similar cardiorenal benefits in Asian and non-Asian patients. <\/jats:p>","DOI":"10.1159\/000532102","type":"journal-article","created":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T21:03:05Z","timestamp":1697058185000},"page":"370-378","source":"Crossref","is-referenced-by-count":16,"title":["Cardiorenal Outcomes with Finerenone in Asian Patients with Chronic Kidney Disease and Type 2 Diabetes: A FIDELIO-DKD post hoc Analysis"],"prefix":"10.1159","volume":"54","author":[{"given":"Daisuke","family":"Koya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan D.","family":"Anker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis M.","family":"Ruilope","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Rossing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ZhiHong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byung Wan","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Te","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlie","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Kolkhof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Lawatscheck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amer","family":"Joseph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertram","family":"Pitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the FIDELIO-DKD Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2023,9,14]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14251"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ki.5000377"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfq189"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaa736"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2025845"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1159\/000503713"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.2174\/1573399814666180709100411"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2010.02.344"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ki.5000097"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2016.10.004"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0194044"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.4065\/mcp.2011.0010"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-021-01345-z"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/eht187"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011161"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1811744"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024816"}],"container-title":["American Journal of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/karger.com\/ajn\/article-pdf\/54\/9-10\/370\/4051711\/000532102.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/karger.com\/ajn\/article-pdf\/54\/9-10\/370\/4051711\/000532102.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T15:32:37Z","timestamp":1745422357000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000532102"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":17,"journal-issue":{"issue":"9-10","published-online":{"date-parts":[[2023,11,27]]},"published-print":{"date-parts":[[2023,11,28]]}},"URL":"https:\/\/doi.org\/10.1159\/000532102","archive":["Portico"],"relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.6084\/m9.figshare.23950851","asserted-by":"subject"}]},"ISSN":["0250-8095","1421-9670"],"issn-type":[{"value":"0250-8095","type":"print"},{"value":"1421-9670","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023]]}}}